AstraZeneca License With Regeneron For VelocImmune Could Spark Industry Trend
This article was originally published in The Pink Sheet Daily
Executive Summary
Regeneron is seeking to sign multiple deals offering access to the next-generation human monoclonal antibody discovery technology, exec tells "The Pink Sheet" DAILY.